SHA:688166

5 stories mentioning SHA:688166Updated 9d ago

Every FINWIRES story that references SHA:688166, newest first.

BrightGene Bio-Medical Technology Shows Positive Results in US, China Clinical Studies

BrightGene Bio-Medical Technology's (SHA:688166) BGM1812 injection for obesity logged positive results in its clinical trial in China and in the U.S., according to a Friday filing with the Shanghai bourse.The drug showed mild to moderate adverse events in China but did not report any adverse events in the U.S., the company said.Trial participants also showed up to 9.2% mean weight loss in the U.S. and up to 8.4% weight reduction among China participants.

SHA:688166

Asia13d ago

BrightGene Bio-Medical Technology Subsidiary Receives China Drug Registration Certificate for COPD Inhalation Spray; Shares Rise 5%

BrightGene Bio-Medical Technology (SHA:688166) subsidiary Aitemei (Suzhou) Pharmaceutical Technology received a drug registration certificate from China's National Medical Products Administration for its tiotropium bromide inhalation spray.The drug is indicated for chronic obstructive pulmonary disease, chronic bronchitis and emphysema, and dyspnea, according to a Saturday filing with the Shanghai bourse.Global sales of the drug, first developed by Boehringer Ingelheim, reached $1.67 billion in 2025, according to market data cited in the filing.Shares rose 5% during afternoon trading on Monday.

SHA:688166

Asia20d ago

BrightGene Gets Registration Certificate for Spray for Chronic Obstructive Pulmonary Disease

BrightGene Bio-Medical Technology (SHA:688166) received a drug registration certificate from China's National Medical Products Administration for tiotropium bromide and olodaterol inhalation spray, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's shares rose 3% at the close of Monday's trade.The drug is used as a long-term maintenance treatment for patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

SHA:688166

Asia90d ago

BrightGene Resubmits Hong Kong IPO Application

BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.The proposed listing still requires regulatory approvals, including from the China Securities Regulatory Commission and Hong Kong's Securities and Futures Commission.BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.Huatai International is the sole sponsor of the proposed IPO.

SHA:688166

Asia102d ago

Participants of BrightGene's Phase 3 Trial See Trimmed Waistlines

Participants of BrightGene Bio-Medical Technology's (SHA:688166) phase 3 clinical trial lost weight and reduced their waistlines during the study, according to a Wednesday disclosure to the Shanghai bourse.The company said the BGM0504 weight loss injection met primary and secondary endpoints during the trial.Blood pressure among participants, who were either overweight or obese, also improved, the filing said.

SHA:688166

Track with the FINWIRES app suite

FolioX

Track SHA:688166 in your portfolio

WheelAI

Analyze SHA:688166 options with the wheel strategy

StockInsider

See market sentiment on SHA:688166